Massimo Freschi
Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele
Papers
3
Total Citations
249
H-Index
3
About
Massimo Freschi is a leading urological researcher whose work centers on improving prostate cancer diagnostics and surgical outcomes. His primary research areas include the clinical utility of prostate-specific antigen (PSA) isoforms—particularly the p2PSA isoform and its derivatives, %p2PSA and the Prostate Health Index (PHI)—as well as the comparative effectiveness of robot-assisted versus open radical prostatectomy. Freschi’s major contributions demonstrate that preoperative p2PSA and PHI can predict pathologic outcomes, such as aggressive tumor features, in patients undergoing radical prostatectomy. His landmark 2011 study (124 citations) and a subsequent multicentric European prospective study (88 citations) established these biomarkers as powerful tools for risk stratification, potentially reducing unnecessary biopsies and overtreatment. Additionally, his evaluation of positive surgical margins across different surgical approaches (37 citations) provides critical insights into optimizing surgical technique. With over 200 combined citations, Freschi’s work has directly influenced clinical guidelines and decision-making, offering urologists and patients more precise prognostic information. His research bridges the gap between biomarker innovation and surgical practice, making him a key figure in the personalized management of prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3